NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

NewcelX, the collaboration partner of ELDN, reported its 2025 financial results, highlighting $2.2 million in cash and a recent $3.4 million financing round. The company is advancing its Type 1 Diabetes program, NCEL-101, which is being developed in collaboration with Eledon Pharmaceuticals, toward IND-enabling milestones.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.